« Previous Next » Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 5 , Pages 651-661 , October 2010

Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell–stimulatory capacity

Corbin Clawson, BS
- Department of Bioengineering, University of California San Diego, La Jolla, California, USA
- These two authors contributed equally to this work.
Chien-Tze Huang, BS
- Moores Cancer Center, University of California San Diego, La Jolla, California, USA
- These two authors contributed equally to this work.
Diahnn Futalan, BS
- Moores Cancer Center, University of California San Diego, La Jolla, California, USA
Daniel Martin Seible, BS
- Department of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, USA
Rebecca Saenz, BS, MS
- Moores Cancer Center, University of California San Diego, La Jolla, California, USA
- Department of Biomedical Sciences, University of California San Diego, La Jolla, California, USA
Marie Larsson, PhD
- Division of Molecular Virology, Department of Clinical and Experimental Medicine, Linköping University, Lindkoeping, Sweden
Wenxue Ma, MD, PhD
- Moores Cancer Center, University of California San Diego, La Jolla, California, USA
Boris Minev, MD
- Moores Cancer Center, University of California San Diego, La Jolla, California, USA
Fiona Zhang, PhD
- Department of Mechanical Engineering, University of California Riverside, Riverside California, USA
Mihri Ozkan, PhD
- Department of Electrical Engineering, University of California Riverside, Riverside, California, USA
Cengiz Ozkan, PhD
- Department of Mechanical Engineering, University of California Riverside, Riverside California, USA
Sadik Esener, PhD
- Department of NanoEngineering, University of California San Diego, La Jolla, California, USA
Davorka Messmer, PhD
- Moores Cancer Center, University of California San Diego, La Jolla, California, USA
- Corresponding author: Moores Cancer Center, University of California San Diego, La Jolla, California 92093-0815, USA.

Received 12 June 2009 ,Accepted 6 March 2010.

To access this article, please choose from the options below

This work is supported by the U.S. Army Medical Research and Materiel Command under Agreement No. W81XWH-07-1-0412 (D.M.); 5 U54 CA119335 from the National Institutes of Health/National Cancer Institute, (S.E.), the Swedish Research Council (VR) AI52731 and the Swedish International Development Cooperation Agency (SIDA) and VINNMER (Vinnova) (M.L.).

Corporate affiliations: Call/Recall Inc., Nanogen, Genoptix, OMM, Orimedix, and Ziva Corp. (S.E.). Corporate affiliations: Call/Recall Inc., Nanogen, Genoptix, OMM, Orimedix, and Ziva Corp. (S.E.).

PII: S1549-9634(10)00097-3

doi: 10.1016/j.nano.2010.03.001

« Previous Next » Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 5 , Pages 651-661 , October 2010